Home › NDC Lookup › RxCUI directory › RxCUI 898490

Potassium citrate 15 MEQ Extended Release Oral Tablet — RxCUI 898490

RxNorm drug concept · Semantic clinical drug
RxCUI 898490 Semantic clinical drug · SCD ● Current RxNorm concept 32 FDA products 62 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI898490
Official namePotassium citrate 15 MEQ Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asK+ citrate 15 MEQ Extended Release Oral Tablet; Pot citrate 15 MEQ Extended Release Oral Tablet; potassium citrate 1620 MG Extended Release Oral Tablet
FDA products mapped32
Package NDCs mapped62
Reported Medicaid activity (SDUD)78,702 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Potassium Citrate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Great question. Potassium citrate works in two main ways. First, it increases the amount of citrate in your urine — citrate acts like a natural stone-fighter by grabbing onto calci...
  • What exactly is potassium citrate doing to stop my kidney stones?
  • Yes, it really does matter. You should take your dose with meals or within 30 minutes after eating — or with a bedtime snack if you have a dose then. Taking it on an empty stomach...
  • Do I have to take this with food? Does it really matter?
📖 Read our full Potassium Citrate guide →

🕸️ Concept Web — How Potassium citrate 15 MEQ Extended Release Oral T... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Potassium citrate 15 MEQ Extended Release Oral Tablet RxCUI 898490

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Potassium citrate 54993
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Urocit-K 220697
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Potassium citrate Extended Release Oral Tablet 373529
    • Potassium citrate Oral Product 1165131
    • Potassium citrate Pill 1165132
    • Potassium citrate Extended Release Oral Tablet [Urocit-K] 542395
    • Urocit-K Oral Product 1186763
    • Urocit-K Pill 1186764
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Potassium citrate 15 MEQ SCDC · 358407
  • Potassium citrate Extended Release Oral Tablet SCDF · 373529
  • Potassium citrate Oral Product SCDG · 1165131
  • Potassium citrate Pill SCDG · 1165132

Brand-Name Concepts

📦 FDA Products & Package NDCs

32 products · 62 package NDCs
62 package NDCs map to RxCUI 898490 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
68382-0538-05 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (68382-538-05) Potassium Citrate Zydus Pharmaceuticals (USA) Inc. 2014-08-12
68382-0538-06 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (68382-538-06) Potassium Citrate Zydus Pharmaceuticals (USA) Inc. 2014-08-12
68382-0538-10 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (68382-538-10) Potassium Citrate Zydus Pharmaceuticals (USA) Inc. 2014-08-12
68382-0538-16 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (68382-538-16) Potassium Citrate Zydus Pharmaceuticals (USA) Inc. 2014-08-12
68382-0538-30 10 BLISTER PACK in 1 CARTON (68382-538-30) / 10 TABLET, EXT... Potassium Citrate Zydus Pharmaceuticals (USA) Inc. 2014-08-12
71335-2897-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (71335-2897-1) POTASSIUM CITRATE Bryant Ranch Prepack 2025-10-23
72162-1759-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (72162-1759-1) Potassium Citrate Bryant Ranch Prepack 2026-03-25
72162-2121-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (72162-2121-1) POTASSIUM CITRATE Bryant Ranch Prepack 2023-09-18
72162-2478-01 100 TABLET in 1 BOTTLE (72162-2478-1) POTASSIUM CITRATE EXTENDED RELEASE Bryant Ranch Prepack 2025-05-01
72865-0191-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (72865-191-01) POTASSIUM CITRATE XLCare Pharmaceuticals, Inc. 2021-02-25
72865-0192-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (72865-192-01) POTASSIUM CITRATE XLCare Pharmaceuticals, Inc. 2021-02-25
72865-0193-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (72865-193-01) POTASSIUM CITRATE XLCare Pharmaceuticals, Inc. 2021-02-25
Observed labelers: Zydus Lifesciences Limited (18) · Zydus Pharmaceuticals (USA) Inc. (18) · Bryant Ranch Prepack (5) · Actavis Pharma, Inc. (3) · Camber Pharmaceuticals, Inc (3) · Golden State Medical Supply, Inc. (3) · +5 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.